⚠️ Teaching Case Note: This case has been de-identified and reconstructed for educational purposes. Clinical details reflect real surgical decision-making and outcomes. Patient identity is fully protected.
From “Inoperable” to Back at the Drawing Board
A 58-year-old architect with a 20 pack-year smoking history — quit five years prior — came in with two months of dry cough, blood-tinged sputum, and exertional breathlessness. For someone whose career demands cognitive sharpness, physical stamina, and long-term quality of life, the diagnosis that followed was devastating: Stage IIIA non-small cell lung cancer, with mediastinal lymph node involvement.
The standard playbook — concurrent chemoradiation followed by immunotherapy consolidation — was on the table. But molecular profiling changed everything.
The Diagnosis: Stage IIIA With a Critical Molecular Finding
Enhanced chest CT and PET-CT revealed a 4.8 cm irregular mass in the right upper lobe, with metabolically active lymph nodes in stations 4R, 7, and 10R. No distant metastases. Clinical staging: cT2bN2M0, Stage IIIA.
CT-guided percutaneous biopsy confirmed invasive adenocarcinoma, non-mucinous type. A 500-gene NGS panel and PD-L1 immunohistochemistry (22C3) were immediately ordered. Results: EGFR exon 19 deletion — positive. ALK, ROS1, BRAF V600E, and KRAS G12C were all negative. PD-L1 TPS was 10% (low). TMB was 4.2 mut/Mb (low), MSS/pMMR.
This molecular profile fundamentally altered the treatment calculus.
The multidisciplinary team — thoracic surgery, medical oncology, radiology, pathology, radiation oncology, and rehabilitation — deliberated carefully. Upfront surgery carried high risk of incomplete resection given the lymph node burden. Standard chemoradiation would bypass the targetable driver mutation entirely. After full informed consent and multidisciplinary discussion, the team selected a precision multimodal pathway: neoadjuvant targeted therapy → dynamic reassessment → surgery → adjuvant targeted maintenance. The patient was simultaneously enrolled in a prospective molecular biomarker registry with standardized imaging and ctDNA monitoring.
The Treatment: Targeted First, Then the Knife
Osimertinib (Tagrisso) 80 mg orally once daily was initiated. Baseline cardiac echo, pulmonary function tests, and ctDNA were documented — circulating tumor DNA variant allele frequency (VAF) measured 3.2%.
The response was rapid and deep.
At week 4, CT showed a 21% reduction in the target lesion. Lymph node metabolic activity had decreased. ctDNA VAF had fallen to 0.8%. At week 8, RECIST 1.1 confirmed partial response — the primary tumor had shrunk by 46%. ctDNA VAF dropped below 0.01%, indicating molecular complete response. The multidisciplinary team reassessed: the patient was now resectable.
Thoracoscopic (VATS) right upper lobectomy with systematic mediastinal lymph node dissection (stations 4R, 7, 10, 11) was performed. Intraoperative frozen section of all nodal stations: no metastatic involvement. Final pathology: ypT1cN0M0. Major pathological response (MPR) — residual viable tumor cells less than 10%. R0 resection confirmed.
Four weeks post-surgery, adjuvant osimertinib 80 mg daily was restarted, planned for three years. Toxicity was manageable throughout: Grade 1 diarrhea and rash, managed with topical corticosteroids and symptomatic treatment. No Grade ≥2 interstitial pneumonitis. No QTc prolongation. No dose reduction required.
Monitoring: Molecular Surveillance Every Step
Post-operative ctDNA was tracked every three months. Four consecutive measurements fell below the limit of detection (≤0.01%). Chest and abdominal CT plus brain MRI were performed every six months.
At six months post-surgery: ECOG PS improved to 0. FACT-L quality of life score rose from 68 to 101. FEV1% predicted recovered to 92% of baseline.
At twelve months: no radiological recurrence. ctDNA remained continuously negative. He had returned to full-time work and resumed weekend hiking and light swimming.
His own words: “From ‘inoperable’ to living normally on a targeted drug — precision medicine gave me back the right to design my own life.”
About Professor Li Jin
Professor Li Jin is Chief of Medical Oncology at Fudan University Shanghai Cancer Center, one of China’s top-ranked oncology institutions. He specializes in lung cancer, targeted therapy, and immunotherapy protocols, and leads multiple national clinical trials on precision oncology. His team is at the forefront of integrating molecular biomarker-driven treatment sequencing for locally advanced NSCLC.
How CMCS Supported This Patient
China Medical Concierge – Shanghai (CMCS) coordinated the full care pathway: case triage and specialist matching at Fudan University Shanghai Cancer Center, MDT scheduling, NGS panel logistics and result interpretation support, on-site Mandarin-English interpretation for all consultations and consent discussions, accommodation near the cancer center, and ongoing follow-up coordination including ctDNA monitoring appointments and adjuvant therapy management.
For international patients navigating complex oncology decisions in China — especially where molecular profiling changes the entire treatment strategy — CMCS provides end-to-end support from first inquiry to long-term surveillance.
📧 contract@medicalsh.com | 📱 WhatsApp | 🌐 medicalsh.com
0 commentaire